Table 1 Comparison of demographic, tumour and lymph node status of patient populations used in development of Friedman et al. tool [16] and melanoma database from Cambridge University Hospital.

From: Systematic review of risk prediction tools for primary cutaneous melanoma outcomes and validation of sentinel lymph node positivity prediction in a UK tertiary cohort

 

Friedman et al. n = 10,108a

CUH Database (≤1 mm only) n = 273a

P-valueb

Age

58 (47–68)

57 (47–66)

0.116

 <55

4166 (41.2%)

126 (46.2%)

 

 ≥55

5942 (58.8%)

147 (53.8%)

 

Sex

  

0.011

 Male

5395 (53.4%)

124 (45.4%)

 

 Female

4713 (46.6%)

149 (54.6%)

 

Breslow

0.8 (0.7-0.9)

0.9 (0.8-1.0)

<0.005

 0.5–0.8

3253 (32.2%)

47 (17.2%)

 

 0.8–1.0

6855 (67.8%)

226 (82.8%)

 

Ulceration

  

0.026

 Absent

9296 (92.0%)

256 (93.8%)

 

 Present

812 (8.0%)

11 (4.0%)

 

 Unknown

0 (0%)

6 (2.2%)

 

Site

  

0.214

 Trunk

3459 (34.2%)

93 (34.1%)

 

 Head and Neck

1608 (15.9%)

32 (11.7%)

 

 Extremity

5012 (49.6%)

148 (54.2%)

 

 Not specified

29 (0%)

0 (0%)

 

 Mitoses

1(0–2)

1 (1,2)

<0.005

 <1

3277 (32.4%)

42 (15.4%)

 

 1

3650 (36.1%)

117 (42.9%)

 

 ≥2

3181 (31.5%)

105 (38.5%)

 

Clark level

  

<0.005

 I/II

929 (9.2%)

6 (2.2%)

 

 III

3645 (36.1%)

88 (32.2%)

 

 IV/V

5534 (54.7%)

132 (48.4%)

 

 Unknown

0 (0%)

47 (17.2%)

 

LVI

  

0.445

 Absent

9943 (98.4%)

250 (91.6%)

 

 Present

165 (1.6%)

2 (0.7%)

 

 Unknown

0 (0%)

21 (7.7%)

 

Regression

  

<0.005

 Absent

6854 (67.8%)

231 (84.6%)

 

 Present

1537 (15.2%)

19 (7.0%)

 

 Unknown

1717 (17.0%)

23 (8.4%)

 

SN Status

 

<0.005

 

 Positive

400 (4.0%)

20 (7.3%)

 

 Negative

9708 (96.0%)

248 (90.8%)

 

 Unknown

0 (0%)

5 (1.8%)

 
  1. Unknown denotes missing values.
  2. aMedian (IQR); n (%),
  3. bchi-squared test or Fisher’s exact test with a significance threshold set at 0.05.
Back to article page